A breathalyser designed to detect the early signs of lung cancer could be available by 2017 – potentially saving thousands of lives.
The device is undergoing clinical trials at 17 British hospitals with the aim of having the non-invasive technology in clinics by the end of next year.
The microchip was developed by scientist Billy Boyle after he tragically lost his wife cancer on Christmas Day in 2014.
The co-founder and CEO of Owlstone Medical developed a microchip sensor technology which sniffs out chemicals associated with a number of cancers.
Diseases such as lung cancer produce minuscule but unique chemical traces.
The breathalyser measures the volatile organic compounds (VOCs) in patients’ exhaled breath.